TY - JOUR T1 - Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2017-000606 VL - 4 IS - 1 SP - e000606 AU - Philip J Mease AU - Dafna D Gladman AU - Ahmed S Samad AU - Laura C Coates AU - Lyrica X H Liu AU - Girish A Aras AU - David H Collier AU - James B Chung Y1 - 2018/02/01 UR - http://rmdopen.bmj.com/content/4/1/e000606.abstract N2 - Objective To evaluate the efficacy of etanercept and methotrexate as monotherapies and as combination therapy in subjects with active psoriatic arthritis (PsA).Methods The Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) is an ongoing, global, double-blind, 48-week, randomised, controlled study. Subjects are randomised (1:1:1) to etanercept monotherapy, methotrexate monotherapy or etanercept-methotrexate combination therapy. Endpoints include rates of ACR20 response and Minimal Disease Activity, measures to characterise extra-articular manifestations (dactylitis, enthesitis, nail disease) and safety.Conclusion SEAM-PsA will characterise the effects of etanercept with and without background methotrexate and methotrexate alone on PsA manifestations, and provide information of practical importance to clinicians on the optimal treatment of PsA. ER -